# Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma

> **NCT00070525** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 90 (estimated)

## Conditions studied

- Childhood High-grade Cerebral Astrocytoma
- Childhood Oligodendroglioma
- Recurrent Childhood Brain Stem Glioma
- Recurrent Childhood Cerebellar Astrocytoma
- Recurrent Childhood Cerebral Astrocytoma
- Recurrent Childhood Medulloblastoma
- Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
- Recurrent Childhood Visual Pathway and Hypothalamic Glioma

## Interventions

- **DRUG:** tipifarnib

## Key facts

- **NCT ID:** NCT00070525
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2006-09
- **Final completion:** —
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2013-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00070525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00070525, "Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00070525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*